Fran Gregory, Pharm.D., MBA is the Vice President of Emerging Therapies at Cardinal Health. She thinks 2024 will be an exciting year for cell and gene therapy.
We asked our readers and some members of our editorial advisory board to make predictions for 2024. Here's what Fran Gregory, Pharm.D., MBA said:
“2024 is going to be an exciting year for cell and gene therapy approvals following a strong end to 2023, including new technology types and indications (sickle cell disease, beta-thalassemia, chronic lymphocytic leukemia and tumor- infiltrating lymphocytes therapy in solid tumors). They all necessitate more precise ways of measuring patient outcomes and improved tracking and visibility for all stakeholders.
We’re anticipating increased payer scrutiny and more of a true focus on innovative payment models given multiple new approvals expected between now and 2025, some of which will be approved in much larger patient populations than we’ve seen so far. Biopharma will continue to focus on earlier and more comprehensive launch planning, including market access and channel strategy to anticipate patient access challenges, build stakeholder education and improve patient services programs to address those needs.”
FDA Updates for Week of May 13: First Bispecific Antibody for Solid Tumor
May 18th 2024The FDA has approved a new type of bispecific antibody to treat small cell lung cancer and an additional indication for Breyanzi for patients with follicular lymphoma. The agency has set review date for gene therapy for enzyme deficiency. In addition, Biogen have Eisai hve begun a rolling submission of subcutaneous Leqembi for Alzheimer’s disease.
Read More
Omega-3s For Dry Eye Disease? Not the Answer According to This Study
May 17th 2024Some research has suggested that omega-3 fatty acid supplements could help treat dry eye disease. But Korean investigators reported results from a randomized clinical trial this week in JAMA Ophthalmology tthat showed no benefit.
Read More